389 related articles for article (PubMed ID: 25487877)
1. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
Acta Ophthalmol; 2015 Jun; 93(4):e254-60. PubMed ID: 25487877
[TBL] [Abstract][Full Text] [Related]
2. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Fukushima A; Suganami H; Araie M;
Acta Ophthalmol; 2016 Feb; 94(1):e26-34. PubMed ID: 26338317
[TBL] [Abstract][Full Text] [Related]
3. Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Suganami H; Araie M;
JAMA Ophthalmol; 2015 Jul; 133(7):755-61. PubMed ID: 25880207
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension.
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
Am J Ophthalmol; 2013 Oct; 156(4):731-6. PubMed ID: 23831221
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy.
Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
J Glaucoma; 2017 Feb; 26(2):96-100. PubMed ID: 27661993
[TBL] [Abstract][Full Text] [Related]
6. Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy.
Sato S; Hirooka K; Nitta E; Ukegawa K; Tsujikawa A
Adv Ther; 2016 Sep; 33(9):1628-34. PubMed ID: 27438467
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Long-Term Ripasudil 0.4% Instillation for the Reduction of Intraocular Pressure in Japanese Open-Angle Glaucoma Patients.
Maruyama Y; Ikeda Y; Mori K; Yoshii K; Ueno M; Sotozono C; Kinoshita S
J Ocul Pharmacol Ther; 2020 May; 36(4):229-233. PubMed ID: 32175792
[No Abstract] [Full Text] [Related]
8. Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study.
Tanihara H; Kakuda T; Sano T; Kanno T; Imada R; Shingaki W; Gunji R
Adv Ther; 2019 Feb; 36(2):333-343. PubMed ID: 30610614
[TBL] [Abstract][Full Text] [Related]
9. Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension.
Clement Freiberg J; von Spreckelsen A; Kolko M; Azuara-Blanco A; Virgili G
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013817. PubMed ID: 35686679
[TBL] [Abstract][Full Text] [Related]
10. Intraocular pressure-lowering effects of Ripasudil: a potential outcome marker for Trabeculotomy.
Goda E; Hirooka K; Mori K; Kiuchi Y
BMC Ophthalmol; 2019 Dec; 19(1):243. PubMed ID: 31791272
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma.
Kusuhara S; Katsuyama A; Matsumiya W; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):809-814. PubMed ID: 29468405
[TBL] [Abstract][Full Text] [Related]
12. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma.
Komizo T; Ono T; Yagi A; Miyata K; Aihara M
Jpn J Ophthalmol; 2019 Jan; 63(1):40-45. PubMed ID: 30368633
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months.
Tanihara H; Kakuda T; Sano T; Kanno T; Kurihara Y
Adv Ther; 2022 Apr; 39(4):1659-1677. PubMed ID: 35150417
[TBL] [Abstract][Full Text] [Related]
14. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
[TBL] [Abstract][Full Text] [Related]
15. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.
Williams RD; Novack GD; van Haarlem T; Kopczynski C;
Am J Ophthalmol; 2011 Nov; 152(5):834-41.e1. PubMed ID: 21794845
[TBL] [Abstract][Full Text] [Related]
16. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.
Inazaki H; Kobayashi S; Anzai Y; Satoh H; Sato S; Inoue M; Yamane S; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2009-2015. PubMed ID: 28711991
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure.
Inoue K; Okayama R; Shiokawa M; Ishida K; Tomita G
Int Ophthalmol; 2018 Feb; 38(1):93-98. PubMed ID: 28063100
[TBL] [Abstract][Full Text] [Related]
18. Morphological change and recovery of corneal endothelial cells after rho-associated protein kinase inhibitor eye-drop (ripasudil 0.4%) instillation.
Maruyama Y; Ikeda Y; Mori K; Yoshii K; Ueno M; Yoshikawa H; Sotozono C; Kinoshita S
Br J Ophthalmol; 2021 Feb; 105(2):169-173. PubMed ID: 32269062
[TBL] [Abstract][Full Text] [Related]
19. Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET).
Araie M; Sugiyama K; Aso K; Kanemoto K; Iwata R; Hollander DA; Senchyna M; Kopczynski CC
Adv Ther; 2023 Oct; 40(10):4639-4656. PubMed ID: 37603205
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]